diabet devic capabl begin converg autom insulin
year american diabet associ meet
devic seem take spotlight focu advanc technolog like
autom insulin deliveri system latest data pipelin underscor
sens capabl converg potenti usher new phase
autom usabl pump cgm grow rapidli clear
endocrin increas use willing prescrib outcom
better devic think devic remov hurdl manual input
prevail think biggest key adopt lower burden time
metric like mard tir time-in-loop glycem variabl cours
matter think like number devic may eventu achiev similar
level measur accept decid factor win
market share may becom eas use simplic fast onboard minim daili
interact accur alert remot softwar upgrad predict capabl
current gener technolog yet offer everyth ada gave us
glimps what alreadi possibl come envis diabet
treatment autom year
spotlight rate studi data
control-iq technolog major focu includ tir patient
use slim control-iq time-in-loop
seem accept enough allow robust adopt particularli sinc
mani patient well real world heard level
discuss sens investor underwhelm given expect
plu time-in-rang find keep play field open
mind buy pt buy pt
other may better number
pipelin provid updat insulin pump compani
also announc partnership privat compani tidepool develop
autom insulin deliveri system admit may challeng
rapidli repair percept part physician
patient diabet devic harder use encourag
manag candid around prior challeng well pipelin focu
simplic eas patient burden target next gen ap time
rang north complet new cgm sensor line
provid updat public privat compani succeed page
updat vlrx price target reflect recent revers stock split base
adjust vlrx model late-may revers stock split revis pre-split price target base
month revenu estim reduc valuat multipl prior reflect financi overhang
around seri warrant pullback stock price follow revers split includ updat model
valuat risk languag
vlrx rate buy price target base month revenu estim assum full share dilut
view revenu multipl conserv given compani forecast strong revenu growth lack regulatori
clinic data risk mani compani grow trade well revenu next quarter
think vlrx share trade around quarterli result updat sale penetr within target territori
meaning revenu contribut ou distribut agreement longer term believ signific room
multipl expans compani continu execut high-touch commerci strategi expand margin
risk rate price target includ dilut relat novemb offer small stand-alone
compani debt warrant potenti competit commerci execut futur capit need
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr profitmargin expansionev/salescagrcompanytickerr ptpricemarket cap
public compani order market cap
abbott host investor meet confer howev analysi three separ studi examin real-
world outcom freestyl libr releas late-break june combin studi analyz effect
libr type patient averag age year old franc germani austria look level
month patient assess use insulin multipl time day averag year compani
highlight late-break first studi look real-world data type patient use libr system
declin averag least three month use
chang base age gender durat insulin use suggest find would applic
notabl neither fda approv materi updat libr offer feel letdown
investor look posit develop alongsid ada meet think necessarili point
issu libr fda continu expect approv near term know week month
away thu expect share remain volatil seen recent run approv
attend investor present meet host manag preview compani
last earn call manag provid color view convinc pipelin pump sensor
develop segment compani reiter revenu growth target fiscal topic
pump compani describ ou commerci minim hybrid closed-loop pump
earli inning repeat expect double-digit growth sinc launch sever
design enhanc intend correct earlier system flaw feel well-known investor clinic
commun near-term compani expect approv advanc hybrid close loop minim fiscal
system featur tir time close loop autom meal handl specif
boast lower optim glucos level mg/dl match level patient train target order see
best outcom increas time auto-mod ensur greater complianc improv abil adjust
miss meal drive proper insulin dose view manag forthcom lesson learn
intent address challeng beyond fiscal look advanc platform even
via fda submiss person close loop pcl tir person therapi adapt auto
mode smartphon control second half fiscal impress describ potenti meal
predict integr data smartphon sensor better inform dose care
cgm portfolio compani confirm plan submit non-adjunct label month guardian sensor
manag also confirm pivot trial commenc new icgm elimin
finger stick use today guardian sensor medtron plan file fda approv first half
fiscal look ahead plan develop new sensor platform call synergi
expect submit fda second half fiscal compani commit make synergi much
user-friendli sensor sever new featur dispos smaller size guardian sensor one-
day calibr easier insert over-tap
prior investor meet announc partnership tidepool privat creat interoper
autom insulin pump compani align fda gain approv interoper system
build tidepool hybrid close loop algorithm call loop posit develop essenti
ensur compat pump sensor algorithm regul fda
told saw detail updat posit feel first mover advantag ap
launch competit cgm could take meaning share increas confid buy rate around
diabet move pt feel risk around upcom paclitaxel discuss expect potenti pull
back near term
attend meet host manag much discuss focus competit dynam
abbott libr platform compani reiter confid offer product pipelin
topic price seem compani continu convers payor includ move toward
pharmaci channel abil give type patient greater access cgm far discuss
benefici price pressur off-set higher patient volum continu expect
keep benefit volum uplift shift toward pharmaci channel least next coupl
quarter though less certain long-term environ alreadi demonstr room
one larger player field think beat number least anoth quarter seem
price toward libr happen may well never happen
also announc collabor companion medic privat integr cgm data insulin
inform companion inpen would allow user see glucos insulin data clariti
diabet manag softwar companion medic insight inpen report
present data omnipod horizon system studi children age year old type diabet
horizon children experienc less time hyperglycemia increas time rang improv nocturn glycem
control versu normal regimen time-in-rang overal overnight time hypoglycem
rang overal overnight view result encourag light competit data
fact fewer devic option young pediatr popul particularli difficult group
come manag diabet
insulet-host sell-sid analyst event much discuss revolv around tandem diabet control-iq data
implic podd horizon project manag emphas pleas see autom insulin
deliveri field advanc control-iq time-in-rang data point clinic meaning light mani patient
hit time-in-rang current avail therapi howev think earli pediatr result
podd horizon well fact omnipod platform on-bodi design mean littl time therapi
stay loop posit horizon continu target potenti commerci launch second half
besid clinic metric manag also emphas import usabl simplic reduc burden
patient think ease-of-us key reason mani patient choos omnipod today expect continu
horizon one factor may posit horizon approach lack lock-in commit period
omnipod dash patient dont up-front cost pay-as-you-go model wont wait
typic four-year period common across diabet devic field would abl move straight horizon
continu like differenti pump offer product pipelin payor/pati access dynam addit
expect type patient becom signific opportun omnipod user think
room emphasi larg under-penetrated portion diabet market
feel hard play share sinc know price may chang believ great
way play larg increas diabet devic autom increas technolog pump stock
perfect one fit bill largest player dispos pump market reiter buy rate
senseon secur non-adjunct claim fda eversens head ada meet use begin
work region dme medicar administr contractor dmac tri attain medicar coverag
technolog non-adjunct claim elimin fingerstick eversens user two daili fingerstick still
requir keep system calibr hear doctor event surround ada meet discuss
import elimin fingerstick manag note signific portion patient estim
come eversens technolog like cgm abbott libr system requir
calibr fingerstick think less hassl cours better fact patient move no-
calibr back twice-daili fingerstick point realiti like mani factor underli decis
choos cgm technolog mani patient like abil hide diseas allow
look forward hear addit learn trend bridg access program
compani earn call believ investor remain focus prescript rate progress payor revenu
ramp upcom need capit think sooner address balanc sheet sooner share may
start work upward compani obtain reimburs win
valerita enter year ada meet announc version ada annual standard
medic diabet includ insulin deliveri use dispos patch-lik devic see win v-go
think could help physician awar adopt improv payor access time seem salesforc
abl discuss addit standard potenti prescrib compani also releas retrospect data
analysi verdict studi look patient switch basal insulin therapi use v-go much like
multipl vlrx studi result analysi show improv without higher total daili dose insulin --
averag reduct patient type diabet
outsid data ada standard believ investor remain focus vlrx revenu growth rate stock
continu trade seri warrant exercis price see ad risk expir deadlin
draw nearer believ manag coupl option avail near-term capit necessari
data tandem slim pump control-iq present ada meet besid result data
freelif kid ap studi also present includ children type diabet year old time rang
week overal baselin overnight time hyperglycemia decreas
time hypoglycemia vs prior sever hypoglycemia mean glucos also
decreas averag time-in-loop see compel pediatr popul
attend meet host manag reflect incred growth pump shipment
last quarter driven part basal-iq technolog believ compani see anoth strong uplift pump
adopt anticip launch control-iq technolog later year may nitpick least
part investor around time-in-rang versu expect head announc dont think
physician patient see way view edg first mover besid
offer sort technolog
beta bionic continu stand us compani make signific progress develop
bihormon autom insulin deliveri system ilet bionic pancrea impress phase data announc
ahead ada home-us studi compar use insulin-onli ilet bihormon insulin
dasiglucagon ilet one week adult patient type diabet bihormon portion lead better
glycem control mg/dl day vs mg/dl insulin-onli portion time hypoglycem rang mg/dl
bihormon portion vs insulin-onli portion time seriou hypoglycemia mg/dl
bihormon portion vs insulin-onli portion phase pivot trial bihormon ilet slate
anticip bihormon ilet launch could come may larg depend regulatori
timelin dasiglucagon compani pharma partner think result replic pivot trial point
game-chang technolog patient
notabl patient phase studi train devic doctor interven improv
manag import factor given complex around current gener diabet devic
appeal featur key opinion leader spoke beta bionics-sponsor event attend ada one
doctor note patient wear ilet littl els enjoy benefit seem unparallel
glucos control allow patient stop think diabet emphas point say
avail doesnt see reason patient use anyth besid ilet unless insur doesnt cover
expect insulin-onli ilet devic come market first potenti fda approv soon first
quarter launch soon assum pivot trial insulin-onli configur start second
quarter
big believ use glucagon realli like beta bionic turn go figur everyth system
believ minim physician time requir get patient start technolog key differenti
bigfoot biomed develop bigfoot uniti bigfoot uniti basal bigfoot autonomi insulin deliveri option
product focus reduc burdensom onboard process patient provid make
easi set adjust maintain use technolog three closest commerci avail
connect pen offer combin abbott libr sensor insulin inject pen connect pen
cap pen cap use perform easi scan libr sensor offer patient key inform like last
took dose dosag recommend dosag deliv recommend dosag small medium larg
meal capac learn patient habit addit bigfoot uniti pen cap allow open system
use differ insulin brand import payor provid patient expect follow
pathway fda potenti clearanc bigfoot autonomi product includ
insulin pump libr sensor bigfoot algorithm autom insulin deliveri expect enter
trial later compani eye fund round expect fund trial oper launch
like beta bionic like idea system requir input simpli turn run figur
treat patient simplic key prescrib patient benefit bigfoot
biolinq develop needle-fre press-on continu glucos monitor approxim size nickel
worn anywher bodi microneedl array sensor go far bodi tradit
instead blood glucos measur taken dermi level biolinq previous rais seri
round conduct two clinic studi technolog includ two-day studi patient studi
patient studi show technolog tight correl standard glucos measur valu
algorithm use retrospect calibr clinic studi plan seri fund
round point pivot studi may slate late potenti fda approv late
biolinq develop appropri algorithm compani confid rival dxcm accuraci yet
proven feel small painless devic mani advantag could help domin cgm market futur
cours good deal work done develop softwar prove type accuraci
cequr paq meal three-day wearabl bolu insulin deliveri well paq total three-day wearabl
deliv basal bolu insulin paq meal fda approv slate limit launch begin next
year compani current seek fund part support launch devic legaci onetouch via
product exclus licens calibra medic johnson johnson rate diabet compani paq
total yet approv use cequr eye potenti submiss fda third quarter
possibl approv around
cnoga develop three busi within one compani includ monitor design non-invas glucos
measur monitor measur bio-paramet hemodynam hematolog
blood gase cloud-bas on-line platform focu non-invas glucos monitor purpos
diabetes-rel note user would insert fingertip monitor receiv read compani
conduct studi demonstr mard use support de novo submiss
fda end juli potenti clearanc launch soon first half
monitor last year expect price approxim
eoflow develop eopatch wearabl insulin pump system three-day dispos deliv basal bolu
insulin eopatch regulatori approv korea pois distributor commerci end
compani intend file submiss third quarter order attain ce mark schedul would put
eopatch path potenti european launch second half like distributor eoflow also
recent receiv fda breakthrough devic design eopancrea system autom insulin deliveri system
develop typezero cgm sensor poctech compani view eopatch open
platform artifici pancrea technolog
glysen develop eclips icgm system fulli implant continu glucos monitor compani focus
improv sensor accuraci implant sensor six patient australia sensor version
repres meaning technic chang prior version sensor chang intend resolv
technolog improv need increas accuraci slate go hand patient later year
australia look ahead patient data two studi encourag glysen intend move
pivot trial icgm system smaller footprint last two year could send read directli
smartphon soon first half
know lab work develop non-invas glucos monitor wearabl earlier year compani announc
uband calori counter avail pre-sal uband calori counter take non-invas glucos measur
data use inform compani research pathway clinic trial work go forward
vlrx incom good asset impair oper tax expens incom stock share net incom net incom analysisgross profit incom revenu oper oper btig estim compani report
vlrx revenu esal geographi unit y/i total patient prescript y/i v-go y/i asp y/i representativesunit per us sale rep growth revenue per us sale btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
